Sanofi India Ltd

Sanofi India Ltd

Sanofi India Ltd has scheduled a Board Meeting on 29th October 2026 to consider and approve the Unaudited Financial Results for the quarter and nine months ended 30th September 2026, and to declare and approve Interim dividend, if any, for the financial year 2026.

Sanofi India Ltd

Sanofi India Ltd has received a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities for the quarter ended 30th September 2026.

Sanofi India Ltd

Sanofi Healthcare India Private Limited, a part of Sanofi India Limited's promoter group, has acquired 3,500,000 equity shares representing 15.20% of Sanofi India Limited's equity share capital from Hoechst GmbH, another promoter of Sanofi India Limited, through a block deal mechanism.

Sanofi India Ltd

Sanofi India Ltd has received a Show Cause Notice from the State Tax Officer alleging discrepancies in GST matters for FY 2022-23, proposing a tax, interest, and penalty demand of Rs.16,40,07,641. The company is examining the notice and does not expect any adverse impact on its financials or operations.

Sanofi India Ltd

Sanofi Healthcare India Private Limited, a part of the promoter group of Sanofi India Limited, has acquired 3,500,000 equity shares representing 15.20% of the equity share capital of Sanofi India Limited from Hoechst GmbH, a promoter of Sanofi India Limited, through a block deal mechanism on the Stock Exchange.

Sanofi India Ltd

Sanofi India Ltd has received a disclosure under Regulation 7(2)(a) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 from Sanofi Healthcare India Private Limited, an entity of the Promoter Group, regarding the purchase of 3,500,000 equity shares of the Company from Hoechst GmbH, a Promoter of the Company, through a block deal mechanism on the Stock Exchange.

Sanofi India Ltd

Sanofi India Ltd has received a disclosure from Hoechst GmbH, a promoter of the company, regarding the transfer of equity shares to Sanofi Healthcare India Private Limited through a block deal mechanism.

Sanofi India Ltd

Sanofi India Ltd received a Show Cause Notice from GST Authorities alleging excess claim of Input Tax Credit for FY 2022-23, with a proposed tax liability of Rs.14,43,01,828 along with interest of Rs.9,30,74,679. The company is in the process of responding to the notice and does not envisage any adverse impact on its financials, operations, or other activities.

Sanofi India Ltd

Sanofi India Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Hoechst GmbH & PACs, indicating a potential change in shareholding.

Sanofi India Ltd

Sanofi India Ltd has received a disclosure under Regulation 29(2) of SEBI (SAST) Regulations, 2011, regarding the purchase of 3,500,000 equity shares of Sanofi India Ltd by Sanofi Healthcare India Private Ltd from Hoechst GmbH, a promoter of the company, through a block deal mechanism on the Stock Exchange.

Sanofi India Ltd

Sanofi Healthcare India Private Limited, part of the promoter group of Sanofi India Limited, has acquired 3,500,000 equity shares representing 15.20% of the equity share capital of Sanofi India Limited from Hoechst GmbH, a promoter of the company, through an inter-se transfer among members of the promoter and promoter group.

Sanofi India Ltd

Sanofi India Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Hoechst GmbH & PACs, indicating a potential change in shareholding.

Sanofi India Ltd

Sanofi India Ltd has announced the closure of its trading window from 1st October 2026 to 48 hours after the announcement of unaudited financial results for the quarter and nine months ending 30th September 2026, in compliance with SEBI regulations.

Sanofi India Ltd

Sanofi India Ltd has received a Show Cause Notice from GST Authorities alleging misclassification of certain products, resulting in a proposed tax liability of Rs. 36,38,70,979 and a penalty of Rs. 36,38,70,979. The company is in the process of responding to the notice and does not envisage any adverse impact on its financials, operations, or other activities.

Sanofi India Ltd

Sanofi India Ltd has disclosed under Regulation 30 of the SEBI (LODR) Regulations that the company has received an order from the Deputy Commissioner, Central Goods & Service Tax, Division –IV, Margao-Goa, accepting the company's application for GST refund without adjusting outstanding demand of Rs.75,63,190 and sanctioning a refund of Rs.1,32,93,535.

Sanofi India Ltd

Sanofi India Ltd has disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that the Assistant Commissioner of Income Tax, TDS OSD TDS Circle 2(2), Mumbai has passed an order giving effect to the favourable action(s) taken, initiated or Appellate Order received from CIT(A) - 49, order(s) passed Mumbai dated 2nd July 2026 for AY 2019-20, dropping the proceedings initiated under Section 201 of the Income-tax Act, 1961 thereby deleting the demand of Rs. 72,71,510.

Sanofi India Ltd

Sanofi India Ltd announced unaudited financial results for the quarter and half year ended 30th June 2026, with a double-digit growth of 14% in the diabetes business, driven by innovative portfolio Toujeo and Soliqua. The company maintained a market leadership position with a 47% market share by value and volume acceleration of 6% with Lantus. The results were presented during an investor conference call on August 5, 2026.

Sanofi India Ltd

Sanofi India Ltd has uploaded the video recording of an investor/analyst call held on August 5, 2026, to discuss unaudited financial results for the quarter and half year ended June 30, 2026, on its website.

Sanofi India Ltd

Sanofi India Ltd has announced its unaudited financial results for the quarter and half year ended 30th June 2026, with total income from operations at ₹312.74 crore and net profit for the period at ₹45.14 crore.

Sanofi India Ltd

Sanofi India Ltd has announced its unaudited financial results for the quarter and half year ended 30th June 2026, showing a strong momentum in its diabetes business with a 8% increase in domestic sales and a 14% growth in public sector sales. The company has also reported a 7% increase in total income for the quarter and a 4% decrease in total income for the half year.